[HTML][HTML] Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF

D Medici, BR Olsen - PloS one, 2012 - journals.plos.org
D Medici, BR Olsen
PloS one, 2012journals.plos.org
Hemangiomas are tumors formed by hyper-proliferation of vascular endothelial cells. This is
caused by elevated vascular endothelial growth factor (VEGF) signaling through VEGF
receptor 2 (VEGFR2). Here we show that elevated VEGF levels produced by hemangioma
endothelial cells are reduced by the mTOR inhibitor rapamycin. mTOR activates p70S6K,
which controls translation of mRNA to generate proteins such as hypoxia inducible factor-1
(HIF-1). VEGF is a known HIF-1 target gene, and our data show that VEGF levels in …
Hemangiomas are tumors formed by hyper-proliferation of vascular endothelial cells. This is caused by elevated vascular endothelial growth factor (VEGF) signaling through VEGF receptor 2 (VEGFR2). Here we show that elevated VEGF levels produced by hemangioma endothelial cells are reduced by the mTOR inhibitor rapamycin. mTOR activates p70S6K, which controls translation of mRNA to generate proteins such as hypoxia inducible factor-1 (HIF-1). VEGF is a known HIF-1 target gene, and our data show that VEGF levels in hemangioma endothelial cells are reduced by HIF-1α siRNA. Over-expression of HIF-1α increases VEGF levels and endothelial cell proliferation. Furthermore, both rapamycin and HIF-1α siRNA reduce proliferation of hemangioma endothelial cells. These data suggest that mTOR and HIF-1 contribute to hemangioma endothelial cell proliferation by stimulating an autocrine loop of VEGF signaling. Furthermore, mTOR and HIF-1 may be therapeutic targets for the treatment of hemangiomas.
PLOS